Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Double Blind, Randomized, Placebo-Controlled, Parallel Group, Flexible Dose Titration, Add-On Study of TC-5214 in the Treatment of MDD With Subjects Who Are Partial Responders or Non-Responders to Citalopram Therapy

NCT00692445 is registered in ClinicalTrials.gov with Targacept Inc. as lead sponsor.

NCT NCT00692445
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00692445 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Double Blind, Randomized, Placebo-Controlled, Parallel Group, Flexible Dose Titration, Add-On Study of TC-5214 in the Treatment of MDD With Subjects Who Are Partial Responders or Non-Responders to Citalopram Therapy
Lead sponsor
Targacept Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2008
Completion date
July 31, 2009
Enrollment
574 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

depression, major depressive disorder